Saturday 17 October 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.9% and free cash flow grew 76.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.37
0.04
−9.76%
Follow TNYA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | 0.00 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(45.33) | (7.78) | — | — | |
P/B ratio |
2.32 | 1.41 | — | — | |
Price to Tangible BV |
2.32 | 1.41 | — | — | |
EV/Sales |
0.00 | 0.00 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(1.58) | (1.07) | — | — | |
EV/FCF |
(1.58) | (1.06) | — | — | |
Quick Ratio |
4.12 | 5.45 | 6.51 | 4.26 | |
Current Ratio |
4.52 | 5.75 | 6.84 | 4.64 | |
Net Debt/EBITDA |
1.84 | 4.42 | 5.31 | 2.97 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.08 | 1.00 | 0.69 | 0.77 | |
Capex/Depreciation |
(0.09) | (0.01) | (0.04) | (0.01) | |
Research and Development Expense of Revenue |
1,495.77% | 6,596.89% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
487.03% | 2,420.89% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
153.24% | 976.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.38 | 0.45 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(71.62%) | (68.12%) | — | — | |
Free Cash Flow Yield |
(32.66%) | (43.19%) | — | — | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.02) | (0.09) | (0.09) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.09) | (0.09) | (0.10) | |
Cash per Share |
0.36 | 0.37 | 0.66 | 0.34 | |
Shareholders Equity per Share |
0.32 | 0.49 | 0.81 | 0.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.32 | 0.49 | 0.81 | 0.51 | |
Free Cash Flow |
(3.71) | (19.24) | (14.01) | (15.62) | |
Working Capital |
66.99 | 79.78 | 90.15 | 48.03 | |
Capital Expenditures |
(0.16) | (0.01) | (0.07) | (0.03) | |
Net Current Asset Value |
61.88 | 67.68 | 81.93 | 39.13 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.14 | 0.05 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
3.10 | 3.49 | 4.37 | 4.34 | |
Average Assets |
107.85 | 139.51 | 133.43 | 122.78 | |
Average Common Equity |
84.62 | 112.79 | 108.06 | 97.74 |
Columns are period end dates